A Placebo-Controlled, Single-Blind Study Evaluating the Safety and Efficacy of Nasal Carbon Dioxide for the Symptomatic Treatment of Classical Trigeminal Neuralgia

Trial Profile

A Placebo-Controlled, Single-Blind Study Evaluating the Safety and Efficacy of Nasal Carbon Dioxide for the Symptomatic Treatment of Classical Trigeminal Neuralgia

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 May 2017

At a glance

  • Drugs Carbon dioxide (Primary)
  • Indications Trigeminal neuralgia
  • Focus Therapeutic Use
  • Sponsors Soleno Therapeutics
  • Most Recent Events

    • 07 Nov 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Dec 2016.
    • 06 Jul 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Nov 2016.
    • 25 Feb 2016 Capnia expects to report top-line data from this trial by the end of 2016, according to a company media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top